Glaukos Corporation (GKOS)
| Market Cap | 7.34B +35.4% |
| Revenue (ttm) | 551.35M +36.3% |
| Net Income | -189.33M |
| EPS | -3.29 |
| Shares Out | 58.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,444,705 |
| Open | 122.67 |
| Previous Close | 121.69 |
| Day's Range | 120.61 - 128.05 |
| 52-Week Range | 73.16 - 148.11 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 154.50 (+23.6%) |
| Earnings Date | Apr 29, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $154.5, which is an increase of 23.60% from the latest price.
News
Glaukos Transcript: Jefferies Global Healthcare Conference 2026
Management is actively addressing concerns with the draft LCD, aiming to align policy with clinical practice and maximize patient access to iDose. Epioxa's launch is progressing ahead of expectations, with strong payer coverage and a transition plan from Photrexa. The company is confident in its pipeline and market position.
Glaukos Transcript: 46th Annual William Blair Growth Stock Conference
The company is driving growth through innovative glaucoma and keratoconus therapies, expanding its product pipeline, and shifting treatment paradigms toward interventional and dropless solutions. Strong financials, new product launches, and a focus on in-office procedures position it for continued expansion.
Glaukos Transcript: AGM 2026
The meeting featured the election of two directors, strong approval of executive compensation, and ratification of the auditor, all by wide margins. No questions were raised by stockholders during the Q&A session.
Glaukos pullback due to concerns about iDose LCD, says William Blair
William Blair notes that Glaukos (GKOS) shares were weak on Friday, May 22, which the firm attributes to investor concerns on last week’s proposed Local Coverage Determination, or LCD, for…
Glaukos Transcript: Stifel 2026 Virtual Ophthalmology Forum
Management is confident that recent restrictive LCD proposals for iDose will be amended through advocacy and clinical evidence, with final impacts likely in 2027. Despite current uncertainty, long-term growth prospects remain strong due to a large addressable market and multiple growth drivers.
Glaukos price target raised to $162 from $141 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $162 from $141 and keeps a Buy rating on the shares. The company’s product pipeline is among the best in…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos Slides: Investor presentation
Glaukos has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
Glaukos price target raised to $153 from $134 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Glaukos (GKOS) to $153 from $134 and keeps a Buy rating on the shares. Glaukos reported strong Q1 results with revenue and…
Glaukos price target raised to $170 from $160 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Glaukos (GKOS) to $170 from $160 and keeps a Buy rating on the shares.
Glaukos price target raised to $140 from $120 at JPMorgan
JPMorgan raised the firm’s price target on Glaukos (GKOS) to $140 from $120 and keeps an Overweight rating on the shares.
Glaukos price target raised to $136 from $127 at Needham
Needham raised the firm’s price target on Glaukos (GKOS) to $136 from $127 and keeps a Buy rating on the shares.
Glaukos price target raised to $141 from $131 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $141 from $131 and keeps a Buy rating on the shares. The company’s Glaucoma and iDose revenue exceeded the firm’s…
Glaukos price target raised to $140 from $135 at Citi
Citi raised the firm’s price target on Glaukos (GKOS) to $140 from $135 and keeps a Buy rating on the shares.
Glaukos reports Q1 EPS (18c), consensus (28c)
Reports Q1 revenue $150.6M, consensus $137.0M. “Our record first quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positi...
Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M
16:27 EDT Glaukos (GKOS) sees FY26 revenue $620M-$635M, consensus $614.4M
Glaukos Earnings Call Transcript: Q1 2026
Record Q1 sales growth of 41% year-over-year led to raised full-year guidance, driven by strong adoption of iDose TR and the Epioxa launch. Investments in commercial expansion, payer coverage, and clinical pipeline support continued momentum and operating leverage.
Glaukos Earnings release: Q1 2026
Glaukos released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Glaukos Quarterly report: Q1 2026
Glaukos has published its Q1 2026 quarterly earnings report on April 29, 2026.
Glaukos Announces First Quarter 2026 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos Proxy statement: Proxy filing
Glaukos filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Glaukos Proxy statement: Proxy filing
Glaukos filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Glaukos Announces the Release of its 2025 Sustainability Report
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos receives permanent J-code for Epioxa
Glaukos (GKOS) Corporation announced the U.S. Centers for Medicare and Medicaid Services has assigned a unique, permanent Healthcare Common Procedure Coding System J-code for Epioxa HD / Epioxa for th...
Glaukos Receives Permanent J-code for Epioxa™
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...